Delstrigo · DIN 02482592 · 100 mg & 300 mg & 300 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Delstrigo · DIN 02482592
Manufacturer: Merck Canada Inc.; listing date 2019-10-31
Health Canada: Marketed since 2018-12-10 · brand DELSTRIGO · ATC J05AR24 LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE · form Tablet · route Oral · ingredients DORAVIRINE 100 MG, LAMIVUDINE 300 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Merck canada inc · schedule Prescription
Delstrigo: Formulary list price $28.79 per unit (the source does not state the unit; exact figure $28.7900). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02482592)
Source record
DIN 02482592: Delstrigo
Raw flags: sec3=Y
Item: 081800395; group id 78; item number 0146; lccId None; manufacturer id MEK
Source form: Tab; strength: 100mg & 300mg & 300mg
Recorded listing: General benefit
Source prices (unrounded): $28.7900; ministry $28.7900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482592
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97302
Shortage status: not checked (no credentials)